BioMarin Pharmaceutical Files 8-K on Security Holder Rights
Ticker: BMRN · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, legal
Related Tickers: BMRN
TL;DR
BioMarin 8-K filed: Changes to security holder rights and corporate docs. Check it out.
AI Summary
BioMarin Pharmaceutical Inc. filed an 8-K on March 3, 2025, reporting events as of February 25, 2025. The filing primarily concerns material modifications to security holders' rights and amendments to its articles of incorporation or bylaws, along with financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in San Rafael, California.
Why It Matters
This filing indicates potential changes affecting BioMarin's security holders and corporate governance, requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and does not immediately suggest significant financial or operational risks.
Key Numbers
- 000-26727 — SEC File Number (Identifies BioMarin's filings with the SEC)
- 68-0397820 — IRS Employer Identification No. (BioMarin's tax identification number)
Key Players & Entities
- BIOMARIN PHARMACEUTICAL INC (company) — Registrant
- February 25, 2025 (date) — Earliest event reported
- March 3, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 770 LINDARO STREET SAN RAFAEL , CALIFORNIA 94901 (address) — Principal executive offices
- 000-26727 (filing_id) — SEC File Number
FAQ
What specific material modifications to the rights of security holders are detailed in this 8-K?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item of disclosure, but the specific details of these modifications are not provided in the excerpt.
What amendments to the company's governing documents are reported?
The filing lists 'Amendments to Articles of Incorporation or Bylaws' as an item, suggesting changes to BioMarin's corporate charter or internal rules.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 25, 2025.
What is BioMarin Pharmaceutical Inc.'s state of incorporation?
BioMarin Pharmaceutical Inc. is incorporated in Delaware.
Where are BioMarin's principal executive offices located?
BioMarin's principal executive offices are located at 770 Lindaro Street, San Rafael, California, 94901.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).